Loading clinical trials...
Loading clinical trials...
Transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved ejection fraction. Its diagnosis is currently based on a non-invasive method including biology and...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pr. Nicolas GIRERD
NCT05797857 · Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
NCT06328075 · Amyloid Cardiomyopathy, Transthyretin Amyloid Cardiomyopathy, and more
NCT07343999 · Transthyretin Cardiac Amyloidosis
Hôpitaux Universitaires Henri Mondor
Créteil
CHRU de Nancy
Nancy
CHU de Rennes Hôpital Pontchaillou
Rennes
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions